Injectable drug may help avoid eye surgery in patients with vitreomacular adhesion.
Genentech, USA. TMorrow@ManagedCareMag.com
Thomas
T
Morrow
D005128:Eye Diseases / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005341:Fibrinolysin / Q000008:administration & dosage* / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000187:drug effects* / Q000473:pathology / Q000601:surgery; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000627:therapeutic use; D000267:Tissue Adhesions / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D057586:Vitreoretinal Surgery / Q000009:adverse effects; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology / Q000601:surgery
D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin